Genor Biopharma's lerociclib approved for breast cancer treatment in China

Genor Biopharma Holdings Limited announced that the NMPA has granted approval for its new drug application for Lerociclib (GB491). Lerociclib is now indicated for treating adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer. The treatment is approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant in patients with disease progression following endocrine therapy. Genor Biopharma believes the approval represents a significant milestone for the company and will provide a better treatment option for patients in China. Lerociclib (GB491) is a novel, highly potent, selective, oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) co-developed by the Group and G1 Therapeutics Inc. for use in combination with endocrine therapy in advanced breast cancer.